Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.

This study has been completed.
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Rennes University Hospital
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT00323804
First received: May 9, 2006
Last updated: September 3, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)